Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Why Gilead Sciences Stock Was a 5% Winner Today
05:29pm, Monday, 15'th Aug 2022
Investors were cheered by late-stage clinical results in breast cancer patients for Trodelvy.
Gilead's stock is up about 4% after sharing new data for cancer drug
03:06pm, Monday, 15'th Aug 2022
Shares of Gilead Sciences Inc. GILD, +4.90% were up 4.9% in trading on Monday after the company said in a news release that Trodelvy improved overall survival rates in people with HR+/HER2- metastatic
Stocks gaining in early trading: Nvidia, AMD, Tesla, Moderna, Gilead
11:01am, Monday, 15'th Aug 2022
Yahoo Finance Live's Brad Smith breaks down how stocks are moving in early trading.
7 Growth Stocks to Buy After a 20% Correction
06:00am, Monday, 15'th Aug 2022
Growth stocks typically generate above-average returns compared to the stock market and their peers. We often find growth stocks in an innovative sector or in a new market that grows faster than conve
3 Healthcare Stocks With High Profit Margins
05:13am, Wednesday, 10'th Aug 2022
If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.
2 Reasons This Beaten-Down Stock Could Be About to Rebound
10:45am, Sunday, 07'th Aug 2022
This drugmaker has more than one trick up its sleeve.
Gilead Sciences to acquire Oxford University biotech spinout MicroBio for $405M
09:48am, Thursday, 04'th Aug 2022
U.S. pharmaceutical giant Gilead Sciences has announced plans to acquire Oxford University biotech spinout company MiroBio in an all-cash deal worth $405 million. MicroBio is a clinical-stage company
Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q2 2022 Results - Earnings Call Transcript
07:58pm, Tuesday, 02'nd Aug 2022
Gilead Sciences, Inc. (NASDAQ:GILD ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Jacquie Ross - VP, IR Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commerc
Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates
06:51pm, Tuesday, 02'nd Aug 2022
Gilead (GILD) delivered earnings and revenue surprises of 4.64% and 6.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Gilead quarterly profit falls as COVID antiviral sales decrease
04:31pm, Tuesday, 02'nd Aug 2022
Gilead Sciences Inc on Tuesday said its second-quarter adjusted profit fell 13% due to higher research and royalty costs as well as a downturn in sales of its COVID-19 antiviral drug Veklury.
August 2022 Stock Considerations
11:56pm, Monday, 01'st Aug 2022
I guess if you call picking the same stocks for the last two or three months as new then, yes
2 Cheap Dividend Stocks Yielding More Than 4%
07:45am, Sunday, 31'st Jul 2022
These two companies haven't performed well in the market recently, but that could be an opportunity for investors.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:40am, Tuesday, 26'th Jul 2022
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Gets Positive CHMP Opinion for Veklury & Tecartus
01:56pm, Monday, 25'th Jul 2022
Gilead (GILD) receives positive CHMP opinion for full marketing authorization of its COVID-19 Jab, Veklury, and for using its CAR-T cell therapy Tecartus to treat relapsed or refractory B-cell precurs
Gilead Sciences: Buy It For The Recession, Buy It For The Dividend
04:23am, Thursday, 21'st Jul 2022
Gilead Sciences reported mediocre results with slightly increasing revenue and slightly increasing adjusted earnings per share. The company is interesting for its dividend and might be a good pick for
